sertraline fluvoxamine — Competitive Intelligence Brief

sertraline fluvoxamine (sertraline fluvoxamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Mental Health.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule

Target snapshot

sertraline fluvoxamine (sertraline fluvoxamine) — Second Affiliated Hospital, School of Medicine, Zhejiang University. This is a combination of two selective serotonin reuptake inhibitors (SSRIs) that increase synaptic serotonin by blocking its reuptake at the presynaptic membrane.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sertraline fluvoxamine TARGET	sertraline fluvoxamine	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Placebo & Citalopram	Placebo & Citalopram	University of Colorado, Denver	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
placebo + fluoxetine	placebo + fluoxetine	University of Florida	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Citalopram HCl	Citalopram HCl	Universitaire Ziekenhuizen KU Leuven	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
SSRI antidepressants	SSRI antidepressants	Nanjing Medical University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class